{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:14:00Z","timestamp":1790802840628,"version":"4.1.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-024-05905-9","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:37:49Z","timestamp":1734136669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Antibiotic treatment of bacterial lung infections in cystic fibrosis"],"prefix":"10.1007","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-5381","authenticated-orcid":false,"given":"Giovanni","family":"Taccetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Dolce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novella","family":"Ravenni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fevola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Francalanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Galici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Silvia","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,14]]},"reference":[{"issue":"18","key":"5905_CR1","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMra2216474","volume":"389","author":"H Grasemann","year":"2023","unstructured":"Grasemann H, Ratjen F (2023) Cystic fibrosis. N Engl J Med 389(18):1693\u20131707. https:\/\/doi.org\/10.1056\/NEJMra2216474","journal-title":"N Engl J Med"},{"issue":"10290","key":"5905_CR2","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","volume":"397","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg M, Haq IJ, Polineni D, Davies JC (2021) Cystic fibrosis. Lancet 397(10290):2195\u20132211. https:\/\/doi.org\/10.1016\/S0140-6736(20)32542-3","journal-title":"Lancet"},{"issue":"1","key":"5905_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","volume":"10","author":"MA Mall","year":"2024","unstructured":"Mall MA, Burgel PR, Castellani C, Davies JC, Salathe M, Taylor-Cousar JL (2024) Cystic fibrosis Nat Rev Dis Primers 10(1):53. https:\/\/doi.org\/10.1038\/s41572-024-00538-6","journal-title":"Cystic fibrosis Nat Rev Dis Primers"},{"key":"5905_CR4","unstructured":"ECFSPR Annual Report 2022, Zolin A, Adamoli A, Bakkeheim E, van Rens J et al (2024) https:\/\/www.ecfs.eu\/sites\/default\/files\/Annual%20Report_2022_ECFSPR_20240603.pdf Accessed 6 November 2024"},{"key":"5905_CR5","doi-asserted-by":"publisher","unstructured":"Campagna G, Amato A, Majo F, Ferrari G, Quattrucci S, Padoan R, Floridia G, Salvatore D, Carnovale V, Puppo Fornaro G, Taruscio D, Salvatore M; Gruppo di lavoro RIFC. Registro Italiano Fibrosi Cistica (RIFC). Rapporto 2021\u20132022 [Italian Cystic Fibrosis Registry (ICFR) 2024 Report 2021\u20132022]. Epidemiol Prev 48(2 Suppl 2):1\u201341. https:\/\/doi.org\/10.19191\/EP24.2.S2.031.","DOI":"10.19191\/EP24.2.S2.031"},{"key":"5905_CR6","unstructured":"UK Cystic Fibrosis Registry 2023 Annual Data Report https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2024-11\/CFT_2023_Annual_Data_Report_Oct2024%201.pdf Accessed 6 November 2024"},{"key":"5905_CR7","unstructured":"Cystic Fibrosis Foundation Patient Registry (2023) Annual Data Report Bethesda, Maryland \u00a92024 Cystic Fibrosis Foundation Accessed 6 November 2024"},{"issue":"2","key":"5905_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1164\/rccm.202312-2326LE","volume":"210","author":"M Mossop","year":"2024","unstructured":"Mossop M, Ish-Horowicz J, Hughes D, Dobra R, Cunanan AG, Rosenthal M, Carr SB, Ramadan N, Nolan LM, Davies JC (2024) Chronicity counts: the impact of Pseudomonas aeruginosa, Staphylococcus aureus, and coinfection in cystic fibrosis. Am J Respir Crit Care Med 210(2):240\u2013242. https:\/\/doi.org\/10.1164\/rccm.202312-2326LE","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"5905_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jcf.2023.02.001","volume":"22","author":"AV Faino","year":"2023","unstructured":"Faino AV, Hoffman LR, Gibson RL, Kronman MP, Nichols DP, Rosenfeld M, Cogen JD (2023) Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbations. J Cyst Fibros 22(4):630\u2013635. https:\/\/doi.org\/10.1016\/j.jcf.2023.02.001","journal-title":"J Cyst Fibros"},{"issue":"1","key":"5905_CR10","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1038\/s41467-024-49150-y","volume":"15","author":"S Widder","year":"2024","unstructured":"Widder S, Carmody LA, Opron K, Kalikin LM, Caverly LJ, LiPuma JJ (2024) Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis. Nat Commun 15(1):4889. https:\/\/doi.org\/10.1038\/s41467-024-49150-y","journal-title":"Nat Commun"},{"issue":"6","key":"5905_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00203-024-03967-9","volume":"206","author":"K Gourari-Bouzouina","year":"2024","unstructured":"Gourari-Bouzouina K, Boucherit-Otmani Z, Halla N, Seghir A, Baba Ahmed-Kazi Tani ZZ, Boucherit K (2024) Exploring the dynamics of mixed-species biofilms involving Candida spp and bacteria in cystic fibrosis. Arch Microbiol 206(6):255. https:\/\/doi.org\/10.1007\/s00203-024-03967-9","journal-title":"Arch Microbiol"},{"issue":"3","key":"5905_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jcf.2019.10.006","volume":"19","author":"E Zemanick","year":"2020","unstructured":"Zemanick E, Burgel PR, Taccetti G, Holmes A, Ratjen F, Byrnes CA, Waters VJ, Bell SC, VanDevanter DR, Stuart Elborn J, Flume PA, Antimicrobial Resistance International Working Group in Cystic Fibrosis (2020) Antimicrobial resistance in cystic fibrosis: a Delphi approach to defining best practices. J Cyst Fibros 19(3):370\u2013375. https:\/\/doi.org\/10.1016\/j.jcf.2019.10.006","journal-title":"J Cyst Fibros"},{"key":"5905_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","volume":"2","author":"TWR Lee","year":"2003","unstructured":"Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM (2003) Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis Patients. J Cyst Fibros 2:29\u201334. https:\/\/doi.org\/10.1016\/S1569-1993(02)00141-8","journal-title":"J Cyst Fibros"},{"issue":"5","key":"5905_CR14","doi-asserted-by":"publisher","first-page":"CD009530","DOI":"10.1002\/14651858.CD009530.pub5","volume":"5","author":"K Jain","year":"2024","unstructured":"Jain K, Wainwright CE, Smyth AR (2024) Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. Cochrane Database Syst Rev 5(5):CD009530. https:\/\/doi.org\/10.1002\/14651858.CD009530.pub5","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"5905_CR15","doi-asserted-by":"publisher","first-page":"CD004197","DOI":"10.1002\/14651858.CD004197.pub6","volume":"6","author":"SC Langton Hewer","year":"2023","unstructured":"Langton Hewer SC, Smith S, Rowbotham NJ, Yule A, Smyth AR (2023) Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 6(6):CD004197. https:\/\/doi.org\/10.1002\/14651858.CD004197.pub6","journal-title":"Cochrane Database Syst Rev"},{"key":"5905_CR16","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R, VX17-445-102 Study Group (2019) Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 381:1809\u20131819. https:\/\/doi.org\/10.1056\/NEJMoa1908639","journal-title":"N Engl J Med"},{"issue":"10212","key":"5905_CR17","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS, VX17-445-103 Trial Group (2019) Efficacy and safety of the Elexacaftor plus Tezacaftor plus Ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394(10212):1940\u20131948. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8","journal-title":"Lancet"},{"issue":"10408","key":"5905_CR18","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","volume":"402","author":"JL Taylor-Cousar","year":"2023","unstructured":"Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG (2023) CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet 402(10408):1171\u20131184. https:\/\/doi.org\/10.1016\/S0140-6736(23)01609-4","journal-title":"Lancet"},{"key":"5905_CR19","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S2213-2600(23)00324-7","volume":"11","author":"KB Hisert","year":"2023","unstructured":"Hisert KB, Birket SE, Clancy JP, Downey DG, Engelhardt JF, Fajac I, Gray RD, Lachowicz-Scroggins ME, Mayer-Hamblett N, Thibodeau P, Tuggle KL, Wainwright CE, De Boeck K (2023) Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy. Lancet Respir Med 11:916\u2013931. https:\/\/doi.org\/10.1016\/S2213-2600(23)00324-7","journal-title":"Lancet Respir Med"},{"issue":"10408","key":"5905_CR20","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","volume":"402","author":"SY Graeber","year":"2023","unstructured":"Graeber SY, Mall MA (2023) The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches. Lancet 402(10408):1185\u20131198. https:\/\/doi.org\/10.1016\/S0140-6736(23)01608-2","journal-title":"Lancet"},{"key":"5905_CR21","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/S2213-2600(23)00297-7","volume":"11","author":"N Mayer-Hamblett","year":"2023","unstructured":"Mayer-Hamblett N, Clancy JP, Jain R, Donaldson SH, Fajac I, Goss CH, Polineni D, Ratjen F, Quon BS, Zemanick ET, Bell SC, Davies JC, Jain M, Konstan MW, Kerper NR, LaRosa T, Mall MA, McKone E, Pearson K, Pilewski JM, Quittell L, Rayment JH, Rowe SM, Taylor-Cousar JL, Retsch-Bogart G, Downey DG (2023) Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective. Lancet Respir Med 11:932\u2013944. https:\/\/doi.org\/10.1016\/S2213-2600(23)00297-7","journal-title":"Lancet Respir Med"},{"key":"5905_CR22","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","volume":"206","author":"MA Mall","year":"2022","unstructured":"Mall MA, Brugha R, Gartner S, Legg J, Moeller A, Mondejar-Lopez P, Prais D, Pressler T, Ratjen F, Reix P, Robinson PD, Selvadurai H, Stehling F, Ahluwalia N, Arteaga-Solis E, Bruinsma BG, Jennings M, Moskowitz SM, Noel S, Tian S, Weinstock TG, Wu P, Wainwright CE, Davies JC (2022) Efficacy and safety of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study. Am J Respir Crit Care Med 206:1361\u20131369. https:\/\/doi.org\/10.1164\/rccm.202202-0392OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"5905_CR23","doi-asserted-by":"publisher","first-page":"e167957","DOI":"10.1172\/JCI167957","volume":"133","author":"DP Nichols","year":"2023","unstructured":"Nichols DP, Morgan SJ, Skalland M, Vo AT, Van Dalfsen JM, Singh SB, Ni W, Hoffman LR, McGeer K, Heltshe SL, Clancy JP, Rowe SM, Jorth P, Singh PK (2023) Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. J Clin Invest 133(10):e167957. https:\/\/doi.org\/10.1172\/JCI167957","journal-title":"J Clin Invest"},{"issue":"1","key":"5905_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","volume":"19","author":"N Volkova","year":"2020","unstructured":"Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C, Higgins M, Konstan MW, Sawicki GS, Elbert A, Charman SC, Marshall BC, Bilton D (2020) Disease progression in patients with cystic fibrosis treated with Ivacaftor: data from national US and UK Registries. J Cyst Fibros 19(1):68\u201379. https:\/\/doi.org\/10.1016\/j.jcf.2019.05.015","journal-title":"J Cyst Fibros"},{"key":"5905_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijid.2023.11.013","volume":"139","author":"AM Dittrich","year":"2024","unstructured":"Dittrich AM, Sieber S, Naehrlich L, Burkhart M, Hafkemeyer S, T\u00fcmmler B, Registry Working Group of the German CF Registry (2024) Use of Elexacaftor\/Tezacaftor\/Ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis. Int J Infect Dis 139:124\u2013131. https:\/\/doi.org\/10.1016\/j.ijid.2023.11.013","journal-title":"Int J Infect Dis"},{"key":"5905_CR26","unstructured":"Laboratory standards for processing microbiological samples from people with cystic fibrosis. Second edition December 2022 https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2023-01\/CF%20Lab%20Standards%20FINAL.pdf Accessed 6 November 2024"},{"key":"5905_CR27","doi-asserted-by":"publisher","first-page":"e0021521","DOI":"10.1128\/cmr.00215-21","volume":"19","author":"L Saiman","year":"2024","unstructured":"Saiman L, Waters V, LiPuma JJ, Hoffman LR, Alby K, Zhang SX, Yau YC, Downey DG, Sermet-Gaudelus I, Bouchara J-P, Kidd TJ, Bell SC, Brown AW (2024) Practical Guidance for Clinical Microbiology Laboratories: updated guidance for processing respiratory tract samples from people with cystic fibrosis. Clin Microbiol Rev 19:e0021521. https:\/\/doi.org\/10.1128\/cmr.00215-21","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"5905_CR28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S2213-2600(18)30171-1","volume":"6","author":"K Ronchetti","year":"2018","unstructured":"Ronchetti K, Tame JD, Paisey C, Thia LP, Doull I, Howe R, Mahenthiralingam E, Forton JT (2018) The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial. Lancet Respir Med 6(6):461\u2013471. https:\/\/doi.org\/10.1016\/S2213-2600(18)30171-1","journal-title":"Lancet Respir Med"},{"issue":"6","key":"5905_CR29","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jcf.2022.09.004","volume":"21","author":"LJ Caverly","year":"2022","unstructured":"Caverly LJ (2022) Considerations for CF airway infection sampling and impact of CFTR modulators. J Cyst Fibros 21(6):906\u2013907. https:\/\/doi.org\/10.1016\/j.jcf.2022.09.004","journal-title":"J Cyst Fibros"},{"key":"5905_CR30","doi-asserted-by":"publisher","unstructured":"Burgel PR, Southern KW, Addy C, Battezzati A, Berry C, Bouchara JP, Brokaar E, Brown W, Azevedo P, Durieu I, Ekkelenkamp M, Finlayson F, Forton J, Gardecki J, Hodkova P, Hong G, Lowdon J, Madge S, Martin C, McKone E, Munck A, Ooi CY, Perrem L, Piper A, Prayle A, Ratjen F, Rosenfeld M, Sanders DB, Schwarz C, Taccetti G, Wainwright C, West NE, Wilschanski M, Bevan A, Castellani C, Drevinek P, Gartner S, Gramegna A, Lammertyn E, Landau EEC, Plant BJ, Smyth AR, van Koningsbruggen-Rietschel S, Middleton PG (2024) Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues. J Cyst Fibros 16:S1569\u20131993(24)00005\u20135. https:\/\/doi.org\/10.1016\/j.jcf.2024.01.005","DOI":"10.1016\/j.jcf.2024.01.005"},{"issue":"7","key":"5905_CR31","doi-asserted-by":"publisher","first-page":"CD011581","DOI":"10.1002\/14651858.CD011581.pub3","volume":"7","author":"MI Ahmed","year":"2018","unstructured":"Ahmed MI, Mukherjee S (2018) Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis. Cochrane Database Syst Rev 7(7):CD011581. https:\/\/doi.org\/10.1002\/14651858.CD011581.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"5905_CR32","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jcf.2017.12.002","volume":"17","author":"D Caudri","year":"2018","unstructured":"Caudri D, Turkovic L, Ng J, de Klerk NH, Rosenow T, Hall GL, Ranganathan SC, Sly PD, Stick SM, Arest CF (2018) The association between Staphylococcus aureus and subsequent bronchiectasis in children with cystic fibrosis. J Cyst Fibros 17(4):462\u2013469. https:\/\/doi.org\/10.1016\/j.jcf.2017.12.002","journal-title":"J Cyst Fibros"},{"issue":"1","key":"5905_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jcf.2012.06.005","volume":"12","author":"CS Dalboge","year":"2013","unstructured":"Dalboge CS, Pressler T, Hoiby N, Nielsen KG, Johansen HK (2013) A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF. J Cyst Fibros 12(1):42\u201348. https:\/\/doi.org\/10.1016\/j.jcf.2012.06.005","journal-title":"J Cyst Fibros"},{"key":"5905_CR34","unstructured":"CF START: a national UK trial to determine whether taking an antibiotic (flucloxacillin) every day predisposes infants with cystic fibrosis (CF) to earlier infection with a bug, Pseudomonas aeruginosa, that is resistant to treatment https:\/\/www.isrctn.com\/ISRCTN18130649 Accessed 6 November 2024"},{"issue":"8","key":"5905_CR35","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1164\/rccm.200802-327OC","volume":"178","author":"EC Dasenbrook","year":"2008","unstructured":"Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP (2008) Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 178(8):814\u2013821. https:\/\/doi.org\/10.1164\/rccm.200802-327OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"23","key":"5905_CR36","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1001\/jama.2010.791","volume":"303","author":"EC Dasenbrook","year":"2010","unstructured":"Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP (2010) Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 303(23):2386\u20132392. https:\/\/doi.org\/10.1001\/jama.2010.791","journal-title":"JAMA"},{"issue":"4","key":"5905_CR37","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/thoraxjnl-2016-208949","volume":"72","author":"MS Muhlebach","year":"2017","unstructured":"Muhlebach MS, Beckett V, Popowitch E, Miller MB, Baines A, Mayer-Hamblett N, Zemanick ET, Hoover WC, VanDalfsen JM, Campbell P, Goss CH, team ST-ts. (2017) Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. Thorax 72(4):318\u2013326. https:\/\/doi.org\/10.1136\/thoraxjnl-2016-208949","journal-title":"Thorax"},{"issue":"3","key":"5905_CR38","doi-asserted-by":"publisher","first-page":"e0213497","DOI":"10.1371\/journal.pone.0213497","volume":"14","author":"D Dolce","year":"2019","unstructured":"Dolce D, Neri S, Grisotto L, Campana S, Ravenni N, Miselli F, Camera E, Zavataro L, Braggion C, Fiscarelli EV, Lucidi V, Cariani L, Girelli D, Faelli N, Colombo C, Lucanto C, Lombardo M, Magazzu G, Tosco A, Raia V, Manara S, Pasolli E, Armanini F, Segata N, Biggeri A, Taccetti G (2019) Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: a randomized multicenter study. PLoS ONE 14(3):e0213497. https:\/\/doi.org\/10.1371\/journal.pone.0213497","journal-title":"PLoS ONE"},{"issue":"6","key":"5905_CR39","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jpeds.2007.04.016","volume":"131","author":"A Elizur","year":"2007","unstructured":"Elizur A, Orscheln RC, Ferkol TW, Atkinson JJ, Dunne WM Jr, Buller RS, Armstrong JR, Mardis ER, Storch GA, Cannon CL (2007) Panton-Valentine Leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Chest 131(6):1718\u20131725. https:\/\/doi.org\/10.1016\/j.jpeds.2007.04.016","journal-title":"Chest"},{"issue":"3","key":"5905_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/thoraxjnl-2014-206750","volume":"71","author":"SL Heltshe","year":"2016","unstructured":"Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA (2016) Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax 71(3):223\u2013229. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-206750","journal-title":"Thorax"},{"key":"5905_CR41","doi-asserted-by":"publisher","unstructured":"Heltshe SL, Saiman L, Popowitch EB, Miller MB, Kloster M, Thompson V, Ferkol TW, Hoover WC, Schechter MS, Muhlebach MS (2014) Outcomes and treatment of chronic methicillin-resistant Staphylococcus aureus differs by staphylococcal cassette chromosome mec (SCCmec) type in children with cystic fibrosis. J Pediatric Infect Dis 1\u20137. J Pediatric Infect Dis Soc 4 (3):225\u201331. https:\/\/doi.org\/10.1093\/jpids\/piu048.","DOI":"10.1093\/jpids\/piu048"},{"key":"5905_CR42","unstructured":"Antibiotic treatment for cystic fibrosis \u2013 3rd edition Report of the UK Cystic Fibrosis Trust Antibiotic Working Group https:\/\/ https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2020-11\/Anitbiotic%20Treatment.pdf Accessed 6 November 2024"},{"key":"5905_CR43","unstructured":"Efficacy and safety study of AeroVanc for the treatment of persistent MRSA lung infection in cystic fibrosis patients https:\/\/clinicaltrials.gov\/study\/NCT01746095?cond=cystic%20fibrosis&intr=Vancomycin&rank=2 Accessed 6 November 2024"},{"key":"5905_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jgar.2021.12.008","volume":"28","author":"MD Esquivel","year":"2022","unstructured":"Esquivel MD, Monogue ML, Smith GS, Finklea JD, Sanders JM (2022) Ceftaroline versus vancomycin for treatment of acute pulmonary exacerbations of cystic fibrosis in adults. J Glob Antimicrob Resist 28:67\u201370. https:\/\/doi.org\/10.1016\/j.jgar.2021.12.008","journal-title":"J Glob Antimicrob Resist"},{"issue":"12","key":"5905_CR45","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1002\/ppul.25029","volume":"55","author":"J Branstetter","year":"2020","unstructured":"Branstetter J, Searcy H, Benner K, Yarbrough A, Crowder C, Troxler B (2020) Ceftaroline vs vancomycin for the treatment of acute pulmonary exacerbations in pediatric patients with cystic fibrosis. Pediatr Pulmonol 55(12):3337\u20133342. https:\/\/doi.org\/10.1002\/ppul.25029.","journal-title":"Pediatr Pulmonol"},{"issue":"Suppl 1","key":"5905_CR46","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1086\/676882","volume":"35","author":"L Saiman","year":"2014","unstructured":"Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ et al (2014) Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 35(Suppl 1):S1\u2013S67. https:\/\/doi.org\/10.1086\/676882","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"5905_CR47","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jcf.2012.04.003","volume":"11","author":"M Rosenfeld","year":"2012","unstructured":"Rosenfeld M, Emerson J, McNamara S, Thompson V, Ramsey BW, Morgan W et al (2012) Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis EPIC observational cohort. J Cyst Fibros 11(5):446\u2013453. https:\/\/doi.org\/10.1016\/j.jcf.2012.04.003","journal-title":"J Cyst Fibros"},{"issue":"1","key":"5905_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/ng.3148","volume":"47","author":"RL Marvig","year":"2015","unstructured":"Marvig RL, Sommer LM, Molin S, Johansen HK (2015) Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. Nat Genet 47(1):57\u201364. https:\/\/doi.org\/10.1038\/ng.3148","journal-title":"Nat Genet"},{"issue":"5","key":"5905_CR49","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1067\/mpd.2001.112897","volume":"138","author":"GM Nixon","year":"2001","unstructured":"Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF et al (2001) Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 138(5):699\u2013704. https:\/\/doi.org\/10.1067\/mpd.2001.112897","journal-title":"J Pediatr"},{"issue":"8769","key":"5905_CR50","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/0140-6736(91)91446-2","volume":"338","author":"NH Valerius","year":"1991","unstructured":"Valerius NH, Koch C, H\u00f8iby N (1991) Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338(8769):725\u2013726. https:\/\/doi.org\/10.1016\/0140-6736(91)91446-2","journal-title":"Lancet"},{"issue":"2","key":"5905_CR51","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/(sici)1099-0496(199802)25:2<88::aid-ppul3>3.0.co;2-j","volume":"25","author":"HG Wiesemann","year":"1998","unstructured":"Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, D\u00f6ring G et al (1998) Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 25(2):88\u201392. https:\/\/doi.org\/10.1002\/(sici)1099-0496(199802)25:2%3c88::aid-ppul3%3e3.0.co;2-j","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"5905_CR52","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/thx.2009.121657","volume":"65","author":"F Ratjen","year":"2010","unstructured":"Ratjen F, Munck A, Kho P, Angyalosi G (2010) Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65(4):286\u2013291. https:\/\/doi.org\/10.1136\/thx.2009.121657","journal-title":"Thorax"},{"issue":"9","key":"5905_CR53","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/archpediatrics.2011.136","volume":"165","author":"MM Treggiari","year":"2011","unstructured":"Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R et al (2011) Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 165(9):847\u2013856. https:\/\/doi.org\/10.1001\/archpediatrics.2011.136","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"10","key":"5905_CR54","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/thoraxjnl-2011-200832","volume":"67","author":"G Taccetti","year":"2012","unstructured":"Taccetti G, Bianchini E, Cariani L, Buzzetti R, Costantini D, Trevisan F et al (2012) Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax 67(10):853\u2013859. https:\/\/doi.org\/10.1136\/thoraxjnl-2011-200832","journal-title":"Thorax"},{"issue":"1","key":"5905_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jcf.2012.06.001","volume":"12","author":"M Proesmans","year":"2013","unstructured":"Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K (2013) Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 12(1):29\u201334. https:\/\/doi.org\/10.1016\/j.jcf.2012.06.001","journal-title":"J Cyst Fibros"},{"issue":"3","key":"5905_CR56","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jcf.2017.01.007","volume":"16","author":"AC Blanchard","year":"2017","unstructured":"Blanchard AC, Horton E, Stanojevic S, Taylor L, Waters V, Ratjen F (2017) Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J Cyst Fibros 16(3):395\u2013400. https:\/\/doi.org\/10.1016\/j.jcf.2017.01.007","journal-title":"J Cyst Fibros"},{"issue":"1","key":"5905_CR57","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jcf.2018.04.002","volume":"18","author":"F Ratjen","year":"2019","unstructured":"Ratjen F, Moeller A, McKinney ML, Asherova I, Alon N, Maykut R et al (2019) Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: the early study. J Cyst Fibros. 18(1):78\u201385. https:\/\/doi.org\/10.1016\/j.jcf.2018.04.002","journal-title":"J Cyst Fibros."},{"issue":"10","key":"5905_CR58","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S2213-2600(20)30331-3","volume":"8","author":"SCL Hewer","year":"2020","unstructured":"Hewer SCL, Smyth AR, Brown M, Jones AP, Hickey H, Kenna D et al (2020) Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial. Lancet Respir Med 8(10):975\u2013986. https:\/\/doi.org\/10.1016\/S2213-2600(20)30331-3","journal-title":"Lancet Respir Med"},{"issue":"9","key":"5905_CR59","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1164\/rccm.201802-0215OC","volume":"198","author":"N Mayer-Hamblett","year":"2018","unstructured":"Mayer-Hamblett N, Retsch-Bogart G, Kloster M, Accurso F, Rosenfeld M, Albers G et al (2018) Azithromycin for early Pseudomonas infection in cystic fibrosis The OPTIMIZE Randomized Trial. Am J Respir Crit Care Med 198(9):1177\u201387. https:\/\/doi.org\/10.1164\/rccm.201802-0215OC","journal-title":"Am J Respir Crit Care Med"},{"key":"5905_CR60","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4193\/Rhino12.207","volume":"51","author":"K Aanaes","year":"2013","unstructured":"Aanaes K, Johansen HK, Skov M, Buchvald FF, Hjuler T, Pressler T et al (2013) Clinical effects of sinus surgery and adjuvant therapy in cystic fibrosis patients - can chronic lung infections be postponed? Rhinology 51:222\u2013230. https:\/\/doi.org\/10.4193\/Rhino12.207","journal-title":"Rhinology"},{"key":"5905_CR61","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1007\/s00405-014-3322-x","volume":"272","author":"K Aanaes","year":"2015","unstructured":"Aanaes K, Eickhardt S, Johansen HK, von Buchwald C, Skov M, H\u00f8iby N et al (2015) Sinus biofilms in patients with cystic fibrosis: is adjusted eradication therapy needed? Eur Arch Otorhinolaryngol 272:2291\u20132297. https:\/\/doi.org\/10.1007\/s00405-014-3322-x","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"5905_CR62","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jcf.2014.02.008","volume":"13","author":"VB Rudkj\u00f8bing","year":"2014","unstructured":"Rudkj\u00f8bing VB, Aanaes K, Wolff TY, von Buchwald C, Johansen HK, Thomsen TR (2014) An exploratory study of microbial diversity in sinus infections of cystic fibrosis patients by molecular methods. J Cyst Fibros 13:645\u2013652. https:\/\/doi.org\/10.1016\/j.jcf.2014.02.008","journal-title":"J Cyst Fibros"},{"key":"5905_CR63","doi-asserted-by":"publisher","unstructured":"Bilton D, Canny G, Conway S, Dumcius S, Hjelte L, Proesmans M, T\u00fcmmler B, Vavrova V, De Boeck K. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials (2011). J Cyst Fibros. 10 Suppl 2:S79\u201381. https:\/\/doi.org\/10.1016\/S1569-1993(11)60012-X.","DOI":"10.1016\/S1569-1993(11)60012-X"},{"issue":"6","key":"5905_CR64","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","volume":"11","author":"G D\u00f6ring","year":"2012","unstructured":"D\u00f6ring G, Flume P, Heijerman H, Elborn JS, Consensus Study Group (2012) Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 11(6):461\u201379. https:\/\/doi.org\/10.1016\/j.jcf.2012.10.004","journal-title":"J Cyst Fibros"},{"issue":"4","key":"5905_CR65","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ppul.21374","volume":"46","author":"DB Sanders","year":"2011","unstructured":"Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH (2011) Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 46(4):393\u2013400. https:\/\/doi.org\/10.1002\/ppul.21374","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"5905_CR66","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","volume":"180","author":"PA Flume","year":"2009","unstructured":"Flume PA et al (2009) Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 180(9):802\u2013808","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"5905_CR67","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/MCP.0000000000000730","volume":"26","author":"C Ng","year":"2020","unstructured":"Ng C, Nadig T, Smyth AR, Flume P (2020) Treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 26(6):679\u2013684. https:\/\/doi.org\/10.1097\/MCP.0000000000000730","journal-title":"Curr Opin Pulm Med"},{"issue":"11","key":"5905_CR68","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","volume":"204","author":"CH Goss","year":"2021","unstructured":"Goss CH, Heltshe SL, West NE, Skalland M, Sanders DB, Jain R, Barto TL, Fogarty B, Marshall BC, VanDevanter DR, Flume PA, STOP2 Investigators (2021) A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment. Am J Respir Crit Care Med 204(11):1295\u20131305. https:\/\/doi.org\/10.1164\/rccm.202102-0461OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"5905_CR69","doi-asserted-by":"publisher","first-page":"CD008319","DOI":"10.1002\/14651858.CD008319.pub4","volume":"8","author":"S Smith","year":"2022","unstructured":"Smith S, Rowbotham NJ, Charbek E (2022) Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev 8(8):CD008319. https:\/\/doi.org\/10.1002\/14651858.CD008319.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"5905_CR70","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jcf.2020.12.012","volume":"20","author":"F Frost","year":"2021","unstructured":"Frost F, Young GR, Wright L, Miah N, Smith DL, Winstanley C, Walshaw MJ, Fothergill JL, Nazareth D (2021) The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: an open-label randomised crossover study (AZTEC-CF). J Cyst Fibros 20(6):994\u20131002. https:\/\/doi.org\/10.1016\/j.jcf.2020.12.012","journal-title":"J Cyst Fibros"},{"issue":"1","key":"5905_CR71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJM199901073400104","volume":"340","author":"BW Ramsey","year":"1999","unstructured":"Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 340(1):23\u201330. https:\/\/doi.org\/10.1056\/NEJM199901073400104","journal-title":"N Engl J Med."},{"issue":"11","key":"5905_CR72","doi-asserted-by":"publisher","first-page":"CD001021","DOI":"10.1002\/14651858.CD001021.pub4","volume":"11","author":"S Smith","year":"2022","unstructured":"Smith S, Rowbotham NJ (2022) Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev 11(11):CD001021. https:\/\/doi.org\/10.1002\/14651858.CD001021.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"5905_CR73","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jcf.2012.07.006","volume":"12","author":"BM Assael","year":"2013","unstructured":"Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, LaRosa M, Knoop C, McElvaney N, Lewis SA, Bresnik M, Montgomery AB, Oermann CM, AZLI Active Comparator Study Group (2013) Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 12(2):130\u201340. https:\/\/doi.org\/10.1016\/j.jcf.2012.07.006","journal-title":"J Cyst Fibros"},{"issue":"4","key":"5905_CR74","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jcf.2014.12.013","volume":"14","author":"J Stuart Elborn","year":"2015","unstructured":"Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA (2015) A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros 14(4):507\u2013514. https:\/\/doi.org\/10.1016\/j.jcf.2014.12.013","journal-title":"J Cyst Fibros"},{"issue":"4","key":"5905_CR75","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jcf.2015.12.004","volume":"15","author":"PA Flume","year":"2016","unstructured":"Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE, Elborn JS (2016) A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros 15(4):495\u2013502. https:\/\/doi.org\/10.1016\/j.jcf.2015.12.004","journal-title":"J Cyst Fibros"},{"issue":"10","key":"5905_CR76","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.clinthera.2016.08.014","volume":"38","author":"JS Elborn","year":"2016","unstructured":"Elborn JS, Vataire AL, Fukushima A, Aballea S, Khemiri A, Moore C, Medic G, Hemels ME (2016) Comparison of inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa lung infection in patients with cystic fibrosis: systematic literature review and network meta-analysis. Clin Ther 38(10):2204\u20132226. https:\/\/doi.org\/10.1016\/j.clinthera.2016.08.014","journal-title":"Clin Ther"},{"issue":"6","key":"5905_CR77","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jcf.2021.05.013","volume":"20","author":"D Bilton","year":"2021","unstructured":"Bilton D, Fajac I, Pressler T, Clancy JP, Sands D, Minic P, Cipolli M, Galeva I, Sol\u00e9 A, Quittner AL, Jumadilova Z, Ciesielska M, Konstan MW, CLEAR-110 Study Group (2021) Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P aeruginosa infection. J Cyst Fibros 20(6):1010\u20131017. https:\/\/doi.org\/10.1016\/j.jcf.2021.05.013","journal-title":"J Cyst Fibros"},{"issue":"6","key":"5905_CR78","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jcf.2016.05.001","volume":"15","author":"PA Flume","year":"2016","unstructured":"Flume PA, Clancy JP, Retsch-Bogart GZ, Tullis DE, Bresnik M, Derchak PA, Lewis SA, Ramsey BW (2016) Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros 15(6):809\u2013815. https:\/\/doi.org\/10.1016\/j.jcf.2016.05.001","journal-title":"J Cyst Fibros"},{"issue":"3","key":"5905_CR79","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jcf.2014.11.005","volume":"14","author":"EC Dasenbrook","year":"2015","unstructured":"Dasenbrook EC, Konstan MW, VanDevanter DR (2015) Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. J Cyst Fibros 14(3):370\u2013375. https:\/\/doi.org\/10.1016\/j.jcf.2014.11.005","journal-title":"J Cyst Fibros"},{"issue":"Suppl 1","key":"5905_CR80","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.jcf.2014.03.010","volume":"13","author":"AR Smyth","year":"2014","unstructured":"Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, Kashirskaya N, Munck A, Ratjen F, Schwarzenberg SJ, Sermet-Gaudelus I, Southern KW, Taccetti G, Ullrich G, Wolfe S, European Cystic Fibrosis Society (2014) European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros 13(Suppl 1):S23-42. https:\/\/doi.org\/10.1016\/j.jcf.2014.03.010","journal-title":"J Cyst Fibros"},{"issue":"2","key":"5905_CR81","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","volume":"17","author":"C Castellani","year":"2018","unstructured":"Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodkov\u00e1 P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P (2018) ECFS best practice guidelines: the 2018 revision. J Cyst Fibros 17(2):153\u2013178. https:\/\/doi.org\/10.1016\/j.jcf.2018.02.006","journal-title":"J Cyst Fibros"},{"issue":"3","key":"5905_CR82","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jcf.2023.11.012","volume":"23","author":"CM Sloan","year":"2024","unstructured":"Sloan CM, Sherrard LJ, Einarsson GG, Dupont LJ, Koningsbruggen-Rietschel SV, Simmonds NJ, Downey DG (2024) Inhaled antimicrobial prescribing for Pseudomonas aeruginosa infections in Europe. J Cyst Fibros 23(3):499\u2013505. https:\/\/doi.org\/10.1016\/j.jcf.2023.11.012","journal-title":"J Cyst Fibros"},{"key":"5905_CR83","doi-asserted-by":"publisher","unstructured":"Lord R, Jones AM, Horsley A (2020) Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Cochrane Database of Systematic Reviews. 4. CD009529. https:\/\/doi.org\/10.1002\/14651858.CD009529.pub4.","DOI":"10.1002\/14651858.CD009529.pub4"},{"issue":"7","key":"5905_CR84","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1128\/JCM.02556-16","volume":"55","author":"BD Edwards","year":"2017","unstructured":"Edwards BD, Greysson-Wong J, Somayaji R, Waddell B, Whelan FJ, Storey DG, Rabin HR, Surette MG, Parkins MD (2017) Prevalence and outcomes of Achromobacter species infections in adults with cystic fibrosis: a North American Cohort Study. J Clin Microbiol 55(7):2074\u20132085. https:\/\/doi.org\/10.1128\/JCM.02556-16","journal-title":"J Clin Microbiol"},{"issue":"11","key":"5905_CR85","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s10096-023-04648-z","volume":"42","author":"V Terlizzi","year":"2023","unstructured":"Terlizzi V, Tomaselli M, Giacomini G, Dalpiaz I, Chiappini E (2023) Stenotrophomonas maltophilia in people with cystic fibrosis: a systematic review of prevalence, risk factors and management. Eur J Clin Microbiol Infect Dis 42(11):1285\u20131296. https:\/\/doi.org\/10.1007\/s10096-023-04648-z","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5905_CR86","doi-asserted-by":"publisher","unstructured":"Graeber SY, Boutin S, Wielp\u00fctz MO, Joachim C, Frey DL, Wege S, Sommerburg O, Kauczor HU, Stahl M, Dalpke AH, Mall MA (2021) Effects of Lumacaftor-Ivacaftor on lung clearance index, magnetic resonance imaging, and airway microbiome in Phe508del homozygous patients with cystic fibrosis. Ann Am Thorac Soc. Jun;18(6):971\u2013980. https:\/\/doi.org\/10.1513\/AnnalsATS.202008-1054OC.","DOI":"10.1513\/AnnalsATS.202008-1054OC"},{"issue":"6","key":"5905_CR87","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jcf.2021.11.003","volume":"21","author":"LM Sosinski","year":"2022","unstructured":"Sosinski LM, Neugebauer KA, Ghuneim LJ, Guzior DV, Castillo-Bahena A, Mielke J, Thomas R, McClelland M, Conrad D, Quinn RA (2022) A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung. J Cyst Fibros 21(6):996\u20131005. https:\/\/doi.org\/10.1016\/j.jcf.2021.11.003","journal-title":"J Cyst Fibros"},{"key":"5905_CR88","unstructured":"Drug development pipeline https:\/\/apps.cff.org\/trials\/pipeline\/ Accessed 6 November 2024"},{"key":"5905_CR89","unstructured":"A Phase 1b\/\u200b2 Trial of the safety and microbiological cctivity of bacteriophage therapy in cystic fibrosis subjects colonized with Pseudomonas aeruginosa https:\/\/clinicaltrials.gov\/search?cond=Cystic%20Fibrosis&term=phage Accessed 6 November 2024"},{"key":"5905_CR90","doi-asserted-by":"publisher","unstructured":"Burgel PR, Ballmann M, Drevinek P, Heijerman H, Jung A, Mainz JG, Peckham D, Plant BJ, Schwarz C, Taccetti G, Smyth A (2024) Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy. BMJ Open Respir Res 3;11(1):e002049. https:\/\/doi.org\/10.1136\/bmjresp-2023-002049.","DOI":"10.1136\/bmjresp-2023-002049"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05905-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-024-05905-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05905-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T03:43:44Z","timestamp":1737690224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-024-05905-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,14]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["5905"],"URL":"https:\/\/doi.org\/10.1007\/s00431-024-05905-9","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,14]]},"assertion":[{"value":"28 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}